Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01268020 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC
A Early Phase 1 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT01268020 is a Early Phase 1 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 5 participants.
The verdict
NCT01268020, a Early Phase 1 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The underlying goal of this study is to assess \[18F\]-FMH3 PET imaging as a tool to evaluate the activity of the H3 receptor in the brain of Alzheimer Disease (AD) research participants
Interventions
- DRUG [18F]-FMH3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2010-12 |
| Est. Completion | 2012-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01268020
The ClinicalTrials.gov registry entry for NCT01268020 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Institute for Neurodegenerative Disorders, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]-FMH3 is the first listed.
NCT01268020 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01268020 about?
NCT01268020 is a clinical study titled "Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC". The underlying goal of this study is to assess \[18F\]-FMH3 PET imaging as a tool to evaluate the activity of the H3 receptor in the brain of Alzheimer Disease (AD) research participants
What is the current status of trial NCT01268020?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2010-12. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01268020?
The interventions under investigation include: [18F]-FMH3 (DRUG).
Who is sponsoring clinical trial NCT01268020?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.